Have a feature idea you'd love to see implemented?
Let us know!
ZNTL Zentalis Pharmaceuticals Inc
Price (delayed)
$3.18
Market cap
$226.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.49
Enterprise value
$223.13M
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of
Highlights
Zentalis Pharmaceuticals's EPS has increased by 46% YoY and by 8% from the previous quarter
Zentalis Pharmaceuticals's net income has increased by 37% YoY and by 8% from the previous quarter
Zentalis Pharmaceuticals's quick ratio has decreased by 19% YoY but it has increased by 12% from the previous quarter
ZNTL's equity is down by 26% YoY and by 7% from the previous quarter
Key stats
What are the main financial stats of ZNTL
Market
Valuations
Earnings
Shares outstanding
71.27M
Market cap
$226.62M
Enterprise value
$223.13M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.64
Price to sales (P/S)
5.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.5
Revenue
$40.56M
EBIT
-$179.04M
EBITDA
-$177.73M
Free cash flow
-$172.09M
Per share
Balance sheet
Liquidity
EPS
-$2.49
Free cash flow per share
-$2.42
Book value per share
$4.98
Revenue per share
$0.57
TBVPS
$6.28
Total assets
$450.66M
Total liabilities
$96.33M
Debt
$40.46M
Equity
$354.33M
Working capital
$345.39M
Debt to equity
0.11
Current ratio
7.29
Quick ratio
7.18
Net debt/EBITDA
0.02
Margins
Efficiency
Dividend
EBITDA margin
-438.2%
Gross margin
100%
Net margin
-442%
Operating margin
-515.9%
Return on assets
-35%
Return on equity
-43.9%
Return on invested capital
-39.7%
Return on capital employed
-45.2%
Return on sales
-441.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZNTL stock price
How has the Zentalis Pharmaceuticals stock price performed over time
Intraday
1.6%
1 week
-19.49%
1 month
-0.63%
1 year
-69.28%
YTD
-79.01%
QTD
-13.59%
Financial performance
How have Zentalis Pharmaceuticals's revenue and profit performed over time
Revenue
$40.56M
Gross profit
$40.56M
Operating income
-$209.27M
Net income
-$179.28M
Gross margin
100%
Net margin
-442%
Zentalis Pharmaceuticals's net income has increased by 37% YoY and by 8% from the previous quarter
The operating income has grown by 26% YoY and by 5% from the previous quarter
The company's net margin rose by 8% QoQ
The operating margin is up by 5% since the previous quarter
Growth
What is Zentalis Pharmaceuticals's growth rate over time
Valuation
What is Zentalis Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.64
P/S
5.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.5
Zentalis Pharmaceuticals's EPS has increased by 46% YoY and by 8% from the previous quarter
The P/B is 86% less than the 5-year quarterly average of 4.6 and 60% less than the last 4 quarters average of 1.6
ZNTL's equity is down by 26% YoY and by 7% from the previous quarter
Efficiency
How efficient is Zentalis Pharmaceuticals business performance
ZNTL's ROIC is up by 41% year-on-year and by 4.6% since the previous quarter
The ROA is up by 32% year-on-year
The ROE rose by 30% year-on-year
Zentalis Pharmaceuticals's ROS has increased by 8% from the previous quarter
Dividends
What is ZNTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZNTL.
Financial health
How did Zentalis Pharmaceuticals financials performed over time
The total assets has contracted by 23% YoY and by 8% from the previous quarter
The current ratio has decreased by 19% YoY but it has increased by 11% from the previous quarter
The company's debt is 89% lower than its equity
ZNTL's equity is down by 26% YoY and by 7% from the previous quarter
The debt to equity has grown by 22% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.